FDA Grants De Novo Authorization to Eyeglass Lenses for People with Episodic Migraine

The Food and Drug Administration (FDA) granted De Novo marketing authorization to Avulux Migraine & Light Sensitivity Lenses (Avulux, Miami, FL), establishing a new device classification for this precision optical filter intended to decrease the impact of light sensitivity in people with episodic migraine.

The lenses are indicated for individuals aged 12 years and older with diagnosed episodic migraine. Avulux is designed to filter light at 480 nm in the high blue range and 590 nm in the red/amber range while transmitting light across the rest of the visible spectrum. The lenses are worn like standard eyeglasses and may be made with or without a vision prescription.

Clinical Use and Access

• The authorization was granted through the FDA De Novo pathway, which applies to novel low- to moderate-risk medical devices without a legally marketed predicate device.
• Avulux is authorized for over-the-counter use and is available through participating eye care providers, optical practices, and authorized partners.
• The device is intended for patients with episodic migraine and light sensitivity, including adolescents aged 12 years and older.
• Avulux should be used alongside standard migraine management and is not intended to replace usual care or medication use.
• The company stated that the FDA reviewed clinical evidence, including randomized controlled trials, as part of the authorization.

Implications for Clinical Practice

The authorization may provide neurologists and other clinicians with a defined, FDA-authorized nonpharmacologic option to discuss with patients who have episodic migraine and clinically meaningful light sensitivity. In practice, the device may be most relevant for patients who report light as a trigger or disabling symptom despite standard acute or preventive treatment.

Source

Avulux. Avulux granted FDA De Novo authorization, creating the first lens classification for migraine-associated light sensitivity. PR Newswire. Published August 24, 2026. Accessed August 27, 2026. https://www.prnewswire.com/news-releases/avulux-granted-fda-de-novo-authorization-creating-the-first-lens-classification-for-migraine-associated-light-sensitivity-302857820.html